Welcome to our dedicated page for Insulet news (Ticker: PODD), a resource for investors and traders seeking the latest updates and insights on Insulet stock.
Insulet Corporation (symbol: PODD) is a pioneering medical device company headquartered in Billerica, Massachusetts. Founded in 2000, the company is dedicated to improving the lives of people with diabetes through its innovative Omnipod Insulin Management System. The Omnipod system revolutionizes insulin pump therapy by making it more accessible and user-friendly compared to traditional methods.
The Omnipod system offers several advantages over multiple daily insulin injections (MDI), including better glycemic control, fewer hypoglycemic events, reduced glycemic variability, and improved quality of life. Despite these benefits, the complexity, cost, and inconvenience of conventional insulin pump technology have deterred many from adopting pump therapy. Insulet's Omnipod addresses these challenges by providing a discreet, tubeless, and easy-to-use system that automates the process and ensures virtually pain-free insertion. The system consists of only two parts that communicate wirelessly, streamlining the user experience.
Since its approval by the U.S. Food and Drug Administration in 2005, the Omnipod has been adopted by approximately 425,000 insulin-dependent diabetics worldwide. This level of adoption underscores the effectiveness and user satisfaction associated with Insulet's flagship product. The Omnipod is notable for its disposable, smartphone-controlled insulin infusion device, which enhances the convenience and flexibility of insulin therapy.
Insulet continues to innovate and expand its product offerings. The company is currently engaged in multiple projects aimed at further improving diabetes management and enhancing the quality of life for its users. Financially, Insulet maintains a strong position, driven by robust sales growth and strategic partnerships that support its mission.
Overall, Insulet Corporation stands out in the medical device industry for its commitment to innovation and its impact on the diabetes community. Investors and stakeholders can expect continued advancements and a strong financial performance as the company pursues its mission to simplify and improve insulin management.
Insulet (NASDAQ: PODD) reported strong financial results for 2024, with full-year revenue reaching $2.1 billion, up 22.1% year-over-year. This marks the company's 9th consecutive year of 20%+ constant currency revenue growth.
Key highlights include:
- Total Omnipod revenue grew 22.4% to $2.0 billion
- U.S. Omnipod revenue increased 20.6% to $1.5 billion
- International Omnipod revenue rose 27.6% to $523.4 million
- Gross margin improved to 69.8%, up 150 basis points
- Net income reached $418.3 million, or $5.78 per diluted share
The company achieved significant milestones, including reaching 500,000 estimated active global customers using Omnipod products, with 365,000 using Omnipod 5. For 2025, Insulet projects revenue growth of 16-20% with gross margin of approximately 70.5% and operating margin of approximately 16.5%.
Insulet (NASDAQ: PODD) has expanded the availability of its Omnipod 5 Automated Insulin Delivery System to five additional European countries: Italy, Denmark, Finland, Norway, and Sweden. The system is now compatible with both Abbott's FreeStyle Libre 2 Plus and Dexcom G6 Continuous Glucose Monitoring sensors, making it the first and only tubeless automated insulin delivery system integrated with both leading CGM sensor brands.
The Omnipod 5 system, indicated for individuals aged two years and older with type 1 diabetes, is currently the number one insulin pump for new users in Europe and the most prescribed AID system in the U.S. The system is waterproof and features proactive glucose control. Clinical results and real-world evidence have shown improvements in A1c levels and time in range while maintaining low hypoglycemia rates.
Insulet (NASDAQ: PODD), the global leader in tubeless insulin pump technology, has scheduled the release of its fourth quarter and full year 2024 financial results for February 20, 2025, after market close. Management will host a conference call at 4:30 p.m. Eastern Time on the same day.
The company's primary product, the Omnipod Insulin Management System, offers a tubeless disposable Pod providing up to three days of continuous insulin delivery. Their flagship innovation, the Omnipod 5 Automated Insulin Delivery System, integrates with continuous glucose monitoring and can be controlled via smartphone in the U.S. or through the Omnipod 5 Controller, eliminating the need for multiple daily injections and fingersticks.
Insulet (NASDAQ: PODD) has won a significant legal victory against EOFlow Co., in the U.S. District Court for the District of Massachusetts. The jury found that EOFlow and other defendants misappropriated Insulet's trade secrets, awarding $452 million in total damages. This includes $170 million in compensatory damages and $282 million in exemplary damages for willful and malicious misappropriation. The verdict came after a four-week trial, though EOFlow's ability to pay the damages remains uncertain.
Insulet (NASDAQ: PODD) announced that its Omnipod 5 Automated Insulin Delivery System is now compatible with Abbott's FreeStyle Libre 2 Plus continuous glucose monitoring sensor in the U.S. This integration makes Omnipod 5 the most connected tubeless AID system in the U.S. and the only AID system indicated for both type 1 and type 2 diabetes. The Omnipod 5 System automatically adjusts insulin delivery every five minutes using SmartAdjust technology, eliminating the need for multiple daily injections while improving diabetes management outcomes.
Insulet (NASDAQ: PODD), the leader in tubeless insulin pump technology, announced its participation in three upcoming investor conferences: The 6th Annual Wolfe Research Healthcare Conference in New York (November 20, 2024), The Nasdaq 51st Investor Conference in London (December 10, 2024), and The J.P. Morgan 43rd Annual Healthcare Conference in San Francisco (January 14, 2025).
The company's flagship product, the Omnipod 5 Automated Insulin Delivery System, offers a unique tubeless insulin delivery solution that integrates with continuous glucose monitoring, requiring no daily injections or fingersticks, and can be controlled via smartphone in the U.S. Live audio webcasts of the presentations will be available on the company's investor relations website.
Insulet (NASDAQ: PODD) reported strong Q3 2024 financial results with revenue reaching $543.9 million, up 25.7% year-over-year. Total Omnipod revenue increased 26.4% to $533.6 million, with U.S. Omnipod revenue up 23.4% to $395.6 million and International revenue up 36.1% to $138.0 million. The company achieved a gross margin of 69.3% and operating income of $88.1 million. Net income was $77.5 million or $1.08 per diluted share. Notably, Omnipod 5 received FDA clearance for type 2 diabetes, becoming the first automated insulin delivery system for both type 1 and type 2 diabetes. The company raised its full-year 2024 revenue growth guidance to 20-21%.
Insulet (NASDAQ: PODD) announces multiple initiatives for National Diabetes Awareness Month and World Diabetes Day in November. Key events include a Nasdaq closing bell ceremony on November 12 featuring Omnipod users from various countries, and an American Diabetes Association panel discussion on November 22-23 in Boston.
The company is launching a new podcast, 'TypeCast: Life Between the Lines,' hosted by Omnipod Ambassador Natalie Balmain. CEO Jim Hollingshead highlighted that 500-600 million adults live with diabetes, projected to exceed 640 million by 2030. Employee initiatives include writing support notes to newly diagnosed individuals and participating in World Diabetes Day activities on November 14.
Insulet (NASDAQ: PODD) has announced the full market release of the Omnipod 5 App for iPhone in the U.S. The app, available for free on the Apple App Store, allows users to fully control their Omnipod 5 Automated Insulin Delivery System directly from compatible iPhones. Users can now perform essential functions like bolusing for meals, changing Pods, and adjusting settings without carrying a separate Controller. The app includes features like Custom Foods for simplified carbohydrate counting and real-time glucose information on the home screen. The system is currently compatible with the Dexcom G6 CGM System and expected to work with Dexcom G7 CGM in 2025.
The diaTribe Foundation has launched the Spoonful of Laughter campaign, a national initiative using comedy to educate about diabetes, counter stereotypes, and reduce stigma. The campaign features six videos showcasing various comedy styles, highlighting common experiences of people with diabetes. It was co-created with advocates, artists, producers, and five comedians, four of whom have diabetes.
The campaign is supported by Insulet, maker of Omnipod® (NASDAQ: PODD). Research shows that up to 80% of people with diabetes report stigmatizing experiences, leading to worse health outcomes and decreased self-care. The initiative aims to replace inaccurate media representations with positive narratives using comedy as an effective tool for promoting change.
FAQ
What is the current stock price of Insulet (PODD)?
What is the market cap of Insulet (PODD)?
What is the main product of Insulet Corporation?
Where is Insulet Corporation headquartered?
When was Insulet Corporation founded?
How does the Omnipod system benefit users compared to multiple daily insulin injections (MDI)?
How many people worldwide use the Omnipod system?
What makes the Omnipod system different from conventional insulin pumps?
When was the Omnipod system approved by the FDA?
How does the Omnipod system enhance user convenience?
What is Insulet Corporation's mission?
What are Insulet Corporation's recent achievements?
